CMRX announced its investigational broad-spectrum antiviral brincidofovir has been selected as one of two investigational agents to be evaluated in a clinical study with ebola. (ISIS) and (AZN) announced a strategic alliance to develop novel delivery methods for antisense oligonucleotides.

AstraZeneca and Pharmacyclics will collaborate on a non-exclusive basis and multiple studies may be considered and conducted. The studies will be led by AstraZeneca.

The average large cap score is 69.53, above the four week moving average score of 62.40. The average large cap stock is trading -10.26% below its 52 week high, 2.58% above its 200 dma, has 3.91 days to cover held short, and is expected to see EPS growth of 11.43% next year.

U.S. stocks extended gains in afternoon trading, as a strong earnings report from Visa Inc. spurred a sharp advance in the Dow industrials.

PFE posted stronger than expected quarterly results, helped by growing sales of its cancer drugs and increase in demand in emerging markets.

Inovio Pharmaceuticals partners with MedImmune to create monoclonal antibodies against various infections.